Drugs / STX-S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07095231 | Aug 2025 → Jun 2026 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STX-S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07095231 ↗ |
| Modality | Vaccine | “A proprietary vaccine developed internally by Capricor” NCT07095231 ↗ |
| Route | Intramuscular | “single intramuscular injection” NCT07095231 ↗ |